 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ORIC-533 / ORIC Pharma
Discovery of ORIC-533, an orally bioavailable CD73 inhibitor with best-in-class profile (Hybrid; Room 355 (Ernest N. Morial Convention Center)) - Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_10080;
P1b
Utilizing ex vivo bone marrow-derived assays from patients with relapsed or refractory MM, ORIC-533 significantly increased immune cell cytotoxicity and reduced autologous myeloma tumor cell viability. Based upon these promising preclinical data, ORIC-533 is being evaluated in Phase 1b clinical trials in patients with relapsed or refractory MM (NCT05227144) and preliminary clinical PK and PD results will be shown.
- ORIC-533 / ORIC Pharma
Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM) (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6214;
P1b
ORIC-533 has demonstrated an acceptable safety profile and preliminary evidence of immune activation in a heavily pretreated RRMM patient population. Enrollment is ongoing and updated data will be presented.
- || ORIC-533 / ORIC Pharma
Trial primary completion date: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 21, 2023
P1b, N=56, Recruiting, Sponsor: ORIC Pharmaceuticals
Enrollment is ongoing and updated data will be presented. Trial primary completion date: Jun 2023 --> Jun 2024
- ORIC-533 / ORIC Pharma
CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma (ENMCC - Hall D) - Nov 4, 2022 - Abstract #ASH2022ASH_6297;
This study, together with our previous reports, confirms that CD73 inhibition can reduce adenosine generation, overcome immune suppression, and restore lysis of MM cells. Based on these results, ORIC-533 is being studied as a single agent in a Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.
- ORIC-533 / ORIC Pharma
ORIC-533, a small molecule CD73 inhibitor with best-in-class properties, reversesimmunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_4161;
Taken together, these results demonstrate that the ORIC CD73 inhibitor potently inhibits the adenosine pathway, which restores anti-tumor immunity and therefore holds potential for patients with MM. Based upon these data, ORIC-533 is being studied as a single agent in a Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma.
- || ORIC-533 / ORIC Pharma
New P1 trial: Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 7, 2022
P1b, N=48, Recruiting, Sponsor: Oric Pharmaceuticals
- ORIC-533 / ORIC Pharma
Optimizations leading to ORIC-533: A potent orally bioavailable CD73 inhibitor that restores anti-tumor immunity in high AMP environments (Room 243-245, Convention Center) - Jan 28, 2022 - Abstract #AACR2022AACR_451;
Based upon these data, ORIC-533 is being studied as a single agent in a Phase 1 clinical trial in patients with relapsed or refractory multiple myeloma. There is no abstract associated with this presentation.
- ORIC-533 / ORIC Pharma
CD73 Inhibition Overcomes Immunosuppression and Triggers Autologous T-Cell Mediated Multiple Myeloma Cell Lysis in the Bone Marrow Milieu (GWCC - Hall B5, Level 1) - Nov 5, 2021 - Abstract #ASH2021ASH_4315;
CD73-mediated adenosine activity suppresses the cytolytic activity of T-cells against tumor cells in the MM BM milieu; and 2. CD73 inhibition can overcome immune suppression and restore lysis of MM cells by autologous T-cells.
- |||| ORIC-533 / ORIC Pharma, AB680 / Arcus Biosci, Gilead
$ORIC #AACR21 (related $RCUS AB680) LB163 - Blocking adenosine production with ORIC-533, a CD73 inhibitor with best-in-class properties, reverses immunosuppression in high-AMP environments (Twitter) - Apr 9, 2021
- ORIC-533 / ORIC Pharma
[VIRTUAL] Blocking adenosine production with ORIC-533, a CD73 inhibitor with best-in-class properties, reverses immunosuppression in high-AMP environments () - Mar 11, 2021 - Abstract #AACR2021AACR_2997;
Taken together, these preclinical results indicate the CD73 inhibitor ORIC-533 has best-in-class properties in reversing immunosuppression in tumors. ORIC-533 is currently undergoing GLP studies to support an IND filing in the first half of 2021.
- CD73 inhibitor / ORIC Pharma
Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production (Grand Ballroom B, Pennsylvania Convention Center) - Feb 13, 2020 - Abstract #ACSSp2020ACS_Sp_14807;
It also rescued AMP-suppressed CD8+ T-cell proliferation as well as cytokine (IFNγ and TNFα) production. Furthermore, OP-5244 blocked CD73-mediated production of adenosine in the TME in vivo.
- CD73 inhibitor / ORIC Pharma
Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73 (Board 166: Level 2 - Hall D) - Oct 25, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_670;
Finally, we showed that a novel, orally bioavailable CD73 inhibitor was able to effectively inhibit AMP to adenosine conversion both in vitro and in vivo, while an anti-CD73 antibody had incomplete effects. Taken together, an orally bioavailable small molecule inhibitor of CD73 represents a potential therapeutic approach to reverse immunosuppression within the tumor microenvironment.